Immunotherapies including PD-1 axis inhibitors in particular have shown some promise in improving outcomes in patients with deficient mismatch repair and high microsatellite instability, but unfortunately this group makes up a small minority of CRC patients. The gene discussed is PDCD1; the disease is colorectal carcinoma.